Deciphering drug resistance in testicular cancer
2023
University Hospital Bonn, Bonn, Germany
Patients suffering from cisplatin-resistant testicular germ cell tumors are facing poor prognosis demanding novel therapeutic options. In this study, a genome-scale CRISPR/Cas9 activation screen on testicular germ cell tumor cell lines was applied to generate cisplatin-resistant clones. Investigation of candidate genes allowed to identify and describe pathways leading to cisplatin resistance.
Testicular germ cell tumor cell lines were treated with a substance inhibiting neddylation, which is a certain form of post-translational protein modification. This treatment increased cisplatin cytotoxicity and sensitized cisplatin-resistant cells towards cisplatin.
This highlights the potential of neddylation inhibitors in combination with cisplatin as a novel treatment option for testicular germ cell tumors.
Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours
Hubert Schorle
Added on: 05-08-2023
[1] https://www.nature.com/articles/s41416-023-02247-5[2] https://www.bionity.com/en/news/1180235/gene-scissors-find-target-for-testicular-cancer-therapy.html?utm_source=newsletter&utm_medium=email&utm_campaign=bionityde&WT.mc_id=ca0264
